Exelixis, Inc. (EXEL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Exelixis, Inc. (EXEL)

EXEL 40.33

+6.4%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dr.praveen who wrote (307)	11/8/2006 8:46:47 AM
From: dr.praveen	of 930

Reference: Exelixis drugs,targets & Indications Drug,Target,Status,Indication XL119* Topoisomerase 2 Phase III Biliary Tract Cancer XL999 VEGFR2, PDGFR,FGFR, FLT3 Phase II Renal Cell Carcinoma, Colon, Ovarian,NSCLC, AML, Multiple Myeloma XL647 VEGFR2, EGFR,HER2 Phase II NSCLC XL784 ADAM10, MMP-2 Phase II Diabetic Nephropathy XL880 c-MET, VEGFR2 Phase II Papillary Cell Carcinoma XL820 c-KIT, VEGFR2,PDGFR Phase I Solid Tumors XL844 CHK1, CHK2 Phase I Solid Tumors, Hematologic Malignancies XL184 c-MET, VEGFR2 Phase I Solid Tumors XL228 ABL, IGF1R, SRC IND Filed Solid Tumors, Hematologic Malignancies XL281 RAF IND Filed Solid Tumors XL418 AKT, S6K Preclinical Solid Tumors XL518 MEK Preclinical Solid Tumors XL765 PI-3K, mTOR Preclinical Solid Tumors XL147 PI-3K Preclinical Solid Tumors XL019 JAK2 Preclinical Myeloid/Lymphoid Malignancies XL550* Mineralocorticoid Receptor Preclinical Hypertension XL335* Farsenoid Receptor Preclinical Atherosclerosis EXEL2255* Liver X Receptor Preclinical Atherosclerosis

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next